Halozyme Therapeutics | Sustainability & Chart

US40637H1095

Basic information on Halozyme Therapeutics

Location: United States

Industry: Health Services

Website

Impact Score

Description Halozyme Therapeutics

Halozyme Therapeutics Inc. is a biopharmaceutical company that focuses on developing and commercializing oncology therapies, drug delivery platforms, and associated technologies to improve treatment outcomes.

Halozyme Therapeutics Sustainability Performance

Climate

34%

Renewable Energy

Halozyme Therapeutics obtains 45% of its energy from renewable energies. Target value per method: min. 100%

Greenhouse Gas Emissions

No data available for Halozyme Therapeutics. Target value per method: max. 100% of CO₂ budget

Supply Chain

No data available for Halozyme Therapeutics. Target value per method: max. 100% of CO₂ budget

Recycling and Recovery of Waste

Halozyme Therapeutics recycles 69% of its waste. Target value per method: min. 75%

Society

44%

Union Formation and Collective Bargaining Power

Halozyme Therapeutics issues 0% collective agreements. Target value per method: min. 80%

CEO Pay Ratio

CEO Helen I. Torley earns 100 times the median salary of employees. Target value per method: max. 30 times

Employee Turnover Rate

Halozyme Therapeutics has an employee turnover rate of 11%. Target value per method: max. 5%

Harassment and Discrimination at the Workplace

Halozyme Therapeutics meets 4 quality criteria for handling harassment and discrimination at the workplace. Target value per method: 4 quality criteria

Gender

75%

Women on Board

Halozyme Therapeutics has 46,2% women across its top leadership and supervisory bodies. Target value per method: min. 40%

Gender Pay Gap

No data available for Halozyme Therapeutics. Target value per method: max. 3%

Women in Management

Halozyme Therapeutics employs 54% female managers. Target value per method: min. 40%

Glass Ceiling

The proportion of women in senior management at Halozyme Therapeutics is 128,6% of the proportion of women in the overall workforce. Target value per method: min. 90%

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

Renewable Energy

Greenhouse Gas Emissions

Supply Chain

Waste Recycling

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.

Compare Halozyme Therapeutics with ...

Halozyme Therapeutics

?

Impact Score

Climate

Society

Gender

34%

44%

75%

Halozyme Therapeutics

?

Impact Score

Climate

Society

Gender

Sources of sustainability performance

Metric	Value	Unit	Year	PDF Name	PDF Page
CEO Pay Ratio
CEO name	Helen I. Torley		2025	sec-def-14a-2025-remuneration-report.pdf	27
CEO-to-median-salary-ratio	100	ratio	2025	sec-def-14a-2025-remuneration-report.pdf	53
Employee Turnover Rate
Voluntary employee turnover	11	%	2025	Halozyme-ESG-2025-FINAL-web.pdf	18
Glass Ceiling
Women in workforce	42	%	2025	Halozyme-ESG-2025-FINAL-web.pdf	7
Women in management	54	%	2025	rev11-Halozyme-ESG-Key-Data-2026_ISS-Corporate-comments_Mar2026-version-1-for-publication.pdf	3
Harassment and Discrimination at the Workplace
Confidentiality mechanisms	Yes		2025	Code-of-Conduct-and-Ethics-Effective-August-3-2026.pdf	15
Incident notification mechanism	Yes		2025	rev11-Halozyme-ESG-Key-Data-2026_ISS-Corporate-comments_Mar2026-version-1-for-publication.pdf	2
Anti-discrimination policy	Yes		2025	Code-of-Conduct-and-Ethics-Effective-August-3-2026.pdf	11
Retaliation safeguards	Yes		2025	Code-of-Conduct-and-Ethics-Effective-August-3-2026.pdf	17
Renewable Energy
Total renewable energy consumption	45	%	2025	rev11-Halozyme-ESG-Key-Data-2026_ISS-Corporate-comments_Mar2026-version-1-for-publication.pdf	8
Union Formation and Collective Bargaining Power
Collective bargaining agreements coverage	0	%	2025	sec-10-k-2025-annual-report.pdf	23
Recycling and Recovery of Waste
Waste recycled	69	%	2025	rev11-Halozyme-ESG-Key-Data-2026_ISS-Corporate-comments_Mar2026-version-1-for-publication.pdf	11
Women on Board
Executive board size	5	people	2025	sec-def-14a-2025-remuneration-report.pdf	27
Women on executive board	2	people	2025	sec-def-14a-2025-remuneration-report.pdf	27
Supervisory board size	8	people	2025	sec-def-14a-2025-remuneration-report.pdf	59
Women on supervisory board	4	people	2025	sec-def-14a-2025-remuneration-report.pdf	59
Women in Management
Women in management	54	%	2025	rev11-Halozyme-ESG-Key-Data-2026_ISS-Corporate-comments_Mar2026-version-1-for-publication.pdf	3

Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.

Find more sustainable companies

Home Find Companies & ETFs Learn to invest Academy Glossary Our Method

Imprint Privacy Policy GTC FAQContact Us

© 2026 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support! Reference data includes information from ESMA FIRDS that has been transformed and enriched by money:care. The use of this reference data does not constitute endorsement of or support for money:care or its products by ESMA. Fund information is based in part on publications by the respective providers and has been processed by money:care. Logos provided by Logo.dev